Viewing Study NCT05952557


Ignite Creation Date: 2025-12-24 @ 7:09 PM
Ignite Modification Date: 2025-12-28 @ 3:55 PM
Study NCT ID: NCT05952557
Status: RECRUITING
Last Update Posted: 2025-06-19
First Post: 2023-05-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module